Associated equity: VolitionRx
Edison Investment Research has terminated coverage on VolitionRx (VNRX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.
VolitionRx — 7 videos in collection
VolitionRX is a multinational epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases, in both humans and other animals, including some cancers and diseases associated with NETosis such as sepsis and COVID-19.
In this webinar, intensive care specialist and haematology key opinion leader Dr Andrew Retter helps us understand the burden of sepsis and challenges in treatment and patient care, the connection between NETosis and sepsis, the future of tools and treatments, as well as the potential role of NETs in other disease areas, and the role of Volition’s diagnostics tools to address unmet need in the space.
Leading the panel and Q&A session is Soo Romanoff, Managing Director of Healthcare at Edison Group.